Immune Tolerance clinical trials

Explore recruiting immune tolerance clinical trials.

Recruiting immune tolerance studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Immune Tolerance trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis

Italy, Germany, Czechia

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

This is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance. (TOLER8)

Sweden, Norway

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

NO EVIDENCE OF DISEASE ACTIVITY AFTER AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE MULTIPLE SCLEROSIS: THE NET-MS STUDY

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An autologous and antigen-specific cell-based therapy of vitamin D3-treated and myelin-derived peptide loaded tolerogenic dendritic cells in subjects with progressive forms of multiple sclerosis: a phase IIa, open-label, self-controlled, multi-center clinical trial.

Belgium, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Immune Tolerance trials by city

Immune Tolerance in Toronto Immune Tolerance in Vancouver Immune Tolerance in Montreal Immune Tolerance in Calgary Immune Tolerance in Edmonton Immune Tolerance in Ottawa Immune Tolerance in Winnipeg Immune Tolerance in Quebec City Immune Tolerance in Hamilton Immune Tolerance in Kitchener Immune Tolerance in London Immune Tolerance in Halifax Immune Tolerance in New York Immune Tolerance in Los Angeles Immune Tolerance in Chicago Immune Tolerance in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease